The neuropsychiatry of Parkinson's disease: advances and challenges

Weintraub, Daniel; Aarsland, Dag; Chaudhuri, K. Ray; Dobkin, Roseanne D.; Leentjens, Albert F.G.; Rodríguez‐Violante, Mayela; Schrag, Anette

doi:10.1016/s1474-4422(21)00330-6

Cited by 185 publications

(115 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Psychologic disorders constitute an important part of PD-associated NMSs. Although the relationship between motor and non-motor symptoms of PD is complex [37] , previous studies have suggested that the most important NMSs of PD (i.e., depression and anxiety) [38] are mainly caused by the main pathology of PD (i.e., dopaminergic system degeneration), so that the NMSs can be a clue for PD onset and severity [39] . In addition, NMSs can aggravate the motor symptoms and affect response to the medications [40] , [41] .…”

Section: Discussionmentioning

confidence: 99%

Psychological outcomes of the COVID-19 pandemic in patients with Parkinson’s disease: A systematic review

Nabizadeh

Seyedalhosseini

Balabandian

et al. 2022

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Psychological outcomes of the COVID-19 pandemic in patients with Parkinson’s disease: A systematic review

Nabizadeh

Seyedalhosseini

Balabandian

et al. 2022

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…This suggests that a new generation of adenosine A 2a receptor antagonists should be used at an earlier point in the progression of PD and in a manner where they are employed to be ‘levodopa sparing’ by avoiding further increases in levodopa dosage when the drug starts to exhibit a loss of efficacy. The other question that needs to be addressed is whether adenosine A 2A antagonists would be effective as early monotherapy, and this has received little attention so far [ 111 , 112 ]. As discussed above, it may be more relevant to utilize an antagonist/inverse agonist for these studies as and when one becomes available for use in PD [ 113 , 114 , 115 ].…”

Section: Clinical Actions Of Adenosine a 2a Antago...mentioning

confidence: 99%

“…Mood disorders are a common feature of PD, with depression affecting at least 35% of the patient population [ 111 , 112 , 127 ]. Depression can be secondary to the changes in quality of life brought on by a diagnosis of PD but may also occur directly due to the progression of pathological change that occurs as the illness advances [ 128 , 129 ].…”

Section: Clinical Actions Of Adenosine a 2a Antago...mentioning

confidence: 99%

The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease

et al. 2022

View full text Add to dashboard Cite

The adenosine A2A receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson’s disease (PD). The selective A2A receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to levodopa/decarboxylase inhibitors in adults with PD experiencing OFF episodes or a wearing-off phenomenon; however, the full potential of this drug class remains to be explored. In this article, we review the pharmacology of adenosine A2A receptor antagonists from the perspective of the treatment of both motor and non-motor symptoms of PD and their potential for disease modification.

show abstract

“…In addition, 5-HT2A receptor gene polymorphisms have been associated with negative symptoms in schizophrenia [ 161 ] and psychotic manifestations in AD [ 162 ]. Pimavanserin, a 5-HT2AR inverse agonist and antagonist, has been approved by the FDA for PDP, further strengthening the hypothesis that serotoninergic system is critically implicated in PDP [ 163 ].…”

Section: Genetic Architecture Of Psychosis In Parkinson’s Diseasementioning

confidence: 99%

Psychosis in Parkinson’s Disease: A Lesson from Genetics

Angelopoulou

Bougea

Papageorgiou

et al. 2022

Genes

View full text Add to dashboard Cite

Psychosis in Parkinson’s disease (PDP) represents a common and debilitating condition that complicates Parkinson’s disease (PD), mainly in the later stages. The spectrum of psychotic symptoms are heterogeneous, ranging from minor phenomena of mild illusions, passage hallucinations and sense of presence to severe psychosis consisting of visual hallucinations (and rarely, auditory and tactile or gustatory) and paranoid delusions. PDP is associated with increased caregiver stress, poorer quality of life for patients and carers, reduced survival and risk of institutionalization with a significant burden on the healthcare system. Although several risk factors for PDP development have been identified, such as aging, sleep disturbances, long history of PD, cognitive impairment, depression and visual disorders, the pathophysiology of psychosis in PD is complex and still insufficiently clarified. Additionally, several drugs used to treat PD can aggravate or even precipitate PDP. Herein, we reviewed and critically analyzed recent studies exploring the genetic architecture of psychosis in PD in order to further understand the pathophysiology of PDP, the risk factors as well as the most suitable therapeutic strategies.

show abstract

The neuropsychiatry of Parkinson's disease: advances and challenges

Cited by 185 publications

References 119 publications

Psychological outcomes of the COVID-19 pandemic in patients with Parkinson’s disease: A systematic review

Psychological outcomes of the COVID-19 pandemic in patients with Parkinson’s disease: A systematic review

The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease

Psychosis in Parkinson’s Disease: A Lesson from Genetics

Contact Info

Product

Resources

About